These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 32846054)

  • 1. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
    Tan D; Gill S; Loh N
    Cancer Med; 2020 Oct; 9(20):7469-7476. PubMed ID: 32846054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer.
    Takeda A; Kunieda E; Fujii H; Yokosuka N; Aoki Y; Oooka Y; Oku Y; Ohashi T; Sanuki N; Mizuno T; Ozawa Y
    Lung Cancer; 2013 Mar; 79(3):248-53. PubMed ID: 23246123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
    Kohutek ZA; Wu AJ; Zhang Z; Foster A; Din SU; Yorke ED; Downey R; Rosenzweig KE; Weber WA; Rimner A
    Lung Cancer; 2015 Aug; 89(2):115-20. PubMed ID: 26078260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
    Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
    J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the usefulness of 18F-fluorodeoxyglucose PET-CT scan after stereotactic body radiotherapy for early-stage non-small cell lung cancer.
    Pastis NJ; Greer TJ; Tanner NT; Wahlquist AE; Gordon LL; Sharma AK; Koch NC; Silvestri GA
    Chest; 2014 Aug; 146(2):406-411. PubMed ID: 24577678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
    Nair VJ; MacRae R; Sirisegaram A; Pantarotto JR
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):312-8. PubMed ID: 24411602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognositc significance of SUV
    Dong M; Liu J; Sun X; Xing L
    J Med Imaging Radiat Oncol; 2017 Oct; 61(5):652-659. PubMed ID: 28266166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT).
    Takeda A; Yokosuka N; Ohashi T; Kunieda E; Fujii H; Aoki Y; Sanuki N; Koike N; Ozawa Y
    Radiother Oncol; 2011 Nov; 101(2):291-7. PubMed ID: 21889224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy.
    Satoh Y; Nambu A; Onishi H; Sawada E; Tominaga L; Kuriyama K; Komiyama T; Marino K; Aoki S; Araya M; Saito R; Maehata Y; Oguri M; Araki T
    Eur J Radiol; 2012 Nov; 81(11):3530-4. PubMed ID: 22178287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
    Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
    Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy.
    Tanaka H; Hayashi S; Hoshi H
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e113-7. PubMed ID: 24176011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
    Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
    J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment
    Satoh Y; Motosugi U; Saito A; Omiya Y; Onishi H
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818794934. PubMed ID: 30222060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small-cell lung cancer patients after stereotactic body radiotherapy.
    Takeda A; Sanuki N; Fujii H; Yokosuka N; Nishimura S; Aoki Y; Oku Y; Ozawa Y; Kunieda E
    J Thorac Oncol; 2014 Jan; 9(1):65-73. PubMed ID: 24346094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.
    Henderson MA; Hoopes DJ; Fletcher JW; Lin PF; Tann M; Yiannoutsos CT; Williams MD; Fakiris AJ; McGarry RC; Timmerman RD
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):789-95. PubMed ID: 19473777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study.
    Takahashi N; Yamamoto T; Matsushita H; Sugawara T; Kubozono M; Umezawa R; Ishikawa Y; Kozumi M; Katagiri Y; Tasaka S; Takeda K; Takeda K; Dobashi S; Jingu K
    J Radiat Res; 2016 Nov; 57(6):655-661. PubMed ID: 27422935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
    Rosen LR; Fischer-Valuck BW; Katz SR; Durci M; Wu HT; Syh J; Syh J; Patel B
    Tumori; 2014; 100(1):42-8. PubMed ID: 24675490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
    Yamamoto T; Kadoya N; Shirata Y; Kaneta T; Koto M; Umezawa R; Ishikawa Y; Kubozono M; Sugawara T; Matsushita H; Abe K; Takeda K; Jingu K
    Ann Nucl Med; 2015 Oct; 29(8):666-73. PubMed ID: 26040413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.